Celldex Therapeutics (CLDX) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$1.01
- EPS estimate
- −$0.90
- EPS surprise
- −12.28%
- Revenue surprise
- −100.00%
- Revenue
- $0.00
- Revenue estimate
- $985,818.00
- Reported
- Nov 10, 2025
Celldex reported Q3 2025 results on November 10, 2025. It posted a loss of $1.01 per share, wider than the expected loss of $0.90, a miss of 12.28%. No revenue figure was reported, against an estimate of about $986,000. A year earlier, in Q3 2024, the loss was $0.64 per share, so the loss widened by about 58%.
Every quarter in the table is a loss. Annual losses grew from $1.64 per share in 2021 to $2.39 in 2022 and $2.91 in 2023, then narrowed to $2.45 in 2024. The first nine months of 2025 lost $2.67, about 53% more than the same period of 2024. Q3 2025 is the largest quarterly loss in the table. Revenue is small and uneven, ranging from $153,000 to $4.1 million a quarter, with $7.1 million for all of 2024. Celldex beat the EPS estimate in 9 of the last 20 quarters and missed in 11.
The table has no report after November 2025. In 2022 through 2025, Celldex reported Q4 between February 26 and February 28. A newer report would show whether the losses kept widening into the end of 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 10, 2025 | −$0.90 | −$1.01 | −12.28% | $0.00 | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.86 | −$0.85 | +0.68% | $730,000.00 | SEC |
| Q1 2025 | May 8, 2025 | −$0.76 | −$0.81 | −7.28% | $695,000.00 | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.74 | −$0.71 | +3.72% | $1.2M | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.67 | −$0.64 | +4.83% | $3.2M | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.59 | −$0.54 | +8.13% | $2.5M | SEC |
| Q1 2024 | May 6, 2024 | −$0.69 | −$0.56 | +19.18% | $200,000.00 | SEC |
| Q4 2023 | Feb 26, 2024 | −$0.73 | −$0.83 | −13.11% | $4.1M | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.68 | −$0.81 | −19.12% | $1.5M | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.66 | −$0.65 | +1.26% | $268,000.00 | SEC |
| Q1 2023 | May 4, 2023 | −$0.62 | −$0.62 | +0.32% | $967,000.00 | SEC |
| Q4 2022 | Feb 28, 2023 | −$0.59 | −$0.56 | +5.08% | $1.6M | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.57 | −$0.57 | −0.58% | $407,000.00 | — |
| Q2 2022 | Aug 8, 2022 | −$0.46 | −$0.77 | −67.39% | $163,000.00 | — |
| Q1 2022 | May 5, 2022 | −$0.45 | −$0.49 | −9.87% | $174,000.00 | — |
| Q4 2021 | Feb 28, 2022 | −$0.42 | −$0.43 | −3.19% | $333,000.00 | — |
| Q3 2021 | Nov 9, 2021 | −$0.36 | −$0.45 | −26.76% | $153,000.00 | — |
| Q2 2021 | Aug 5, 2021 | −$0.40 | −$0.34 | +15.00% | $3.5M | — |
| Q1 2021 | May 6, 2021 | −$0.35 | −$0.42 | −21.74% | $685,000.00 | — |
| Q4 2020 | Mar 29, 2021 | −$0.37 | −$0.55 | −49.99% | $3.8M | — |
Quarterly revenue
Frequently asked questions
When did Celldex Therapeutics (CLDX) last report earnings?
Celldex Therapeutics last reported on Nov 10, 2025, covering fiscal Q3 2025.
Did CLDX beat earnings estimates?
No. Celldex Therapeutics reported EPS of −$1.01 for Q3 2025 against a −$0.90 estimate — a 12.28% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.